Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 5
2010 2
2011 2
2012 2
2013 1
2014 4
2015 6
2016 4
2017 11
2018 5
2019 6
2020 5
2021 5
2022 6
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
Imoto S, Wang K, Bi XW, Liu G, Im YH, Im SA, Sim SH, Ueno T, Futamura M, Toi M, Fujiwara Y, Ahn SG, Lee JE, Park YH, Takao S, Oba MS, Kitagawa Y, Nishiyama M. Imoto S, et al. Among authors: takao s. Breast Cancer. 2023 May;30(3):412-423. doi: 10.1007/s12282-023-01436-7. Epub 2023 Jan 23. Breast Cancer. 2023. PMID: 36689066
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N. Kikawa Y, et al. Among authors: takao s. PLoS One. 2022 Nov 29;17(11):e0278344. doi: 10.1371/journal.pone.0278344. eCollection 2022. PLoS One. 2022. PMID: 36445924 Free PMC article.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: takao s. Int J Clin Oncol. 2022 Nov;27(11):1793. doi: 10.1007/s10147-022-02237-2. Int J Clin Oncol. 2022. PMID: 36166110 Free PMC article. No abstract available.
Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.
Yamada K, Kaise H, Taguchi T, Horiguchi J, Takao S, Suzuki M, Kubota T, Miura D, Narui K, Tawaraya K, Machida Y, Akazawa K, Kohno N, Ishikawa T; JONIE Study Group. Yamada K, et al. Among authors: takao s. J Bone Miner Metab. 2022 Nov;40(6):998-1006. doi: 10.1007/s00774-022-01366-y. Epub 2022 Aug 30. J Bone Miner Metab. 2022. PMID: 36042056 Clinical Trial.
Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
Soyama H, Nishio M, Otani J, Sakuma T, Takao S, Hara S, Masuda T, Mimori K, Toyokuni S, Lydon JP, Nakao K, Nishina H, Fukumoto T, Maehama T, Suzuki A. Soyama H, et al. Among authors: takao s. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2123134119. doi: 10.1073/pnas.2123134119. Epub 2022 Jul 11. Proc Natl Acad Sci U S A. 2022. PMID: 35858357 Free PMC article.
Correction to: Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.
Tsuda H, Kurosumi M, Akiyama F, Ohno S, Saji S, Masuda N, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T. Tsuda H, et al. Among authors: takao s. Breast Cancer. 2022 Jul;29(4):730. doi: 10.1007/s12282-022-01367-9. Breast Cancer. 2022. PMID: 35499664 Free PMC article. No abstract available.
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.
Tsuda H, Kurosumi M, Akiyama F, Ohno S, Saji S, Masuda N, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T. Tsuda H, et al. Among authors: takao s. Breast Cancer. 2022 Jul;29(4):720-729. doi: 10.1007/s12282-022-01350-4. Epub 2022 Apr 18. Breast Cancer. 2022. PMID: 35435571 Free PMC article.
58 results